Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention

Simple item page
dc.contributor.authorOnwuka, Shakira R.
dc.contributor.authorMcIntosh, Jennifer
dc.contributor.authorMacrae, Finlay
dc.contributor.authorChondros, Patty
dc.contributor.authorBoyd, Lucy
dc.contributor.authorWijesuriya, Rushani
dc.contributor.authorSaya, Sibel
dc.contributor.authorKarnchanachari, Napin
dc.contributor.authorNovy, Kitty
dc.contributor.authorJenkins, Mark A.
dc.contributor.authorWalter, Fiona M.
dc.contributor.authorTrevena, Lyndal
dc.contributor.authorGutierrez, Javiera Martinez
dc.contributor.authorBroun, Kate
dc.contributor.authorFishman, George
dc.contributor.authorMarker, Julie
dc.contributor.authorEmery, Jon
dc.date.accessioned2025-01-20T16:13:44Z
dc.date.available2025-01-20T16:13:44Z
dc.date.issued2024
dc.description.abstractBackground Australian guidelines recommend that people aged 50-70 years consider taking low-dose aspirin to reduce their risk of colorectal cancer (CRC). Aim To determine the effect of a consultation with a researcher before an appointment in general practice using a decision aid presenting the benefits and harms of taking low- dose aspirin compared with a general CRC prevention brochure on patients' informed decision making and low- dose aspirin use. Design and setting Individually randomised controlled trial in six general practices in Victoria, Australia, from October 2020 to March 2021. Method Participants were recruited from a consecutive sample of patients aged 50-70 years attending a GP. The intervention was a consultation using a decision aid to discuss taking aspirin to reduce CRC risk while control consultations discussed reducing CRC risk generally. Self-reported co-primary outcomes were the proportion of individuals making informed choices about taking aspirin at 1 month and on low-dose aspirin uptake at 6 months, respectively. The intervention effect was estimated using a generalised linear model and reported with Bonferroni-adjusted 95% confidence intervals (CIs) and P-values. Results A total of 261 participants (86% of eligible patients) were randomised into trial arms (n n = 129 intervention; n = 132 control). Of these participants, 17.7% (n n = 20/113) in the intervention group and 7.6% (n n = 9/118) in the control group reported making an informed choice about taking aspirin at 1 month, an estimated 9.1% (95% CI = 0.29 to 18.5) between- arm difference in proportions (odds ratio [OR] 2.47, 97.5% CI = 0.94 to 6.52, P = 0.074). The proportions of individuals who reported taking aspirin at 6 months were 10.2% (n n = 12/118) of the intervention group versus 13.8% (n n = 16/116) of the control group, an estimated between-arm difference of -4.0% (95% CI = -13.5 to 5.5; OR 0.68 [97.5% CI = 0.27 to 1.70, P = 0.692]). Conclusion The decision aid improved informed decision making but this did not translate into long-term regular use of aspirin to reduce CRC risk. In future research, decision aids should be delivered alongside various implementation strategies.
dc.fuente.origenWOS
dc.identifier.doi10.3399/BJGP.2023.0385
dc.identifier.eissn1478-5242
dc.identifier.issn0960-1643
dc.identifier.urihttps://doi.org/10.3399/BJGP.2023.0385
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90403
dc.identifier.wosidWOS:001266256400001
dc.issue.numero745
dc.language.isoen
dc.pagina.finalE507
dc.pagina.inicioE498
dc.revistaBritish journal of general practice
dc.rightsacceso restringido
dc.subjectaspirin
dc.subjectcolorectal cancer
dc.subjectdecision aid
dc.subjectgeneral practice
dc.subjectinformed decision making
dc.subjectrandomised controlled trial
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleShould I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention
dc.typeartículo
dc.volumen74
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas